PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Maekmoondong-tang (a formula containing Ophiopogon japonicus) is used to improve cough symptoms [PMID:26666732]
Ophiopogonin D reduces inflammation and prevents ALI in mouse models [PMID:38824823, PMID:40099394]
Ophiopogon japonicus and Mai-Men-Dong decoction inhibit pulmonary inflammation and regulate ferroptosis in mice [PMID:31930023, PMID:41448369]
Extracts and active compounds exhibit potential anticancer effects and suppress tumor growth and metastasis in vitro and in vivo [PMID:36854203]
Ophiopogonin D promotes osteoblast proliferation and reduces osteoclastic gene expression in murine models [PMID:25582622]
Root extract inhibits muscle loss and improves muscle strength in obese mice [PMID:41470891]
Evidence summary
PubMed sources
- 1.PMID: 31030757 (2019) — The structures and biological functions of polysaccharides from traditional Chinese herbs. · Progress in molecular biology and translational science
- 2.PMID: 21202304 (2008) — (E)-3-(4-Hydr-oxy-3-methoxy-benzyl-idene)-4-(4-hydroxy-phen-yl)pyrrolidin-2-one. · Acta crystallographica. Section E, Structure reports online
- 3.PMID: 39101149 (2024) — Ophiopogonin D: review of pharmacological activity. · Frontiers in pharmacology
- 4.PMID: 35530141 (2022) — Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling. · Acta pharmaceutica Sinica. B
- 5.PMID: 26826325 (2016) — Ophiopogon japonicus--A phytochemical, ethnomedicinal and pharmacological review.